MicroRNAs As Biomarkers for Metabolic Disorders in Polycystic Ovary Syndrome (PCOS): A Review

Overview

Journal Med Sci Monit

Specialties General Medicine
Pathology

Date 2024 Dec 22

PMID 39709519

Authors

Izabela Dymanowska

Karolina Frankowska

Agata Malgorzata Krawczyk

Julia Kociuba

Paulina Gil-Kulik

Beata Banaszewska

Grzegorz Polak

Affiliations

Soon will be listed here.

Abstract

Polycystic ovary syndrome (PCOS) is associated with several mild metabolic disorders, including insulin resistance (IR), obesity, and dyslipidemia, as well as with some more severe ones, including type 2 diabetes mellitus, non-alcoholic fatty liver disease (NAFLD), and cardiovascular disease. Clinically, mild metabolic complications of PCOS such as IR or lipid metabolism disorders are the predictors of these more severe ones. So far, there is no reliable single marker that enables defining metabolic risk in patients with PCOS. Therefore, novel independent markers of metabolic disturbances are needed. Most reports have focused on microRNA (miRNA, miR) assessment in blood serum or granulosa cells, suggesting the high potential clinical utility of such management. The greatest number of studies focused on the association between miRNAs and IR, obesity, or lipid disorders, and some miRNAs were characteristics of all these processes concomitantly. The altered expression of miR-222, miR-223, miR-320, and miR-122 has been most commonly mentioned as the regulator of these metabolic distortions and seems to result from common regulation pathways of metabolic disturbances. In turn, the current literature lacked the miRNA which could be identified as a reliable marker of type 2 diabetes mellitus or NAFLD accompanying PCOS. Therefore, the main objective of future studies should be determining miRNA markers of these most serious metabolic complications. This article aims to review the role of microRNAs as biomarkers for metabolic disorders in PCOS.

References

Lewandowski K, Skowronska-Jozwiak E, Lukasiak K, Galuszko K, Dukowicz A, Cedro M . How much insulin resistance in polycystic ovary syndrome? Comparison of HOMA-IR and insulin resistance (Belfiore) index models. Arch Med Sci. 2019; 15(3):613-618. PMC: 6524173. DOI: 10.5114/aoms.2019.82672. View

Mendrick D, Diehl A, Topor L, Dietert R, Will Y, La Merrill M . Metabolic Syndrome and Associated Diseases: From the Bench to the Clinic. Toxicol Sci. 2017; 162(1):36-42. PMC: 6256950. DOI: 10.1093/toxsci/kfx233. View

Rashad N, Ateya M, Saraya Y, Elnagar W, Helal K, Lashin M . Association of miRNA - 320 expression level and its target gene endothelin-1 with the susceptibility and clinical features of polycystic ovary syndrome. J Ovarian Res. 2019; 12(1):39. PMC: 6505291. DOI: 10.1186/s13048-019-0513-5. View

Baneu P, Vacarescu C, Dragan S, Cirin L, Lazar-Hocher A, Cozgarea A . The Triglyceride/HDL Ratio as a Surrogate Biomarker for Insulin Resistance. Biomedicines. 2024; 12(7). PMC: 11274455. DOI: 10.3390/biomedicines12071493. View

Veie C, Nielsen I, Frisk N, Dalgaard L . Extracellular microRNAs in Relation to Weight Loss-A Systematic Review and Meta-Analysis. Noncoding RNA. 2023; 9(5). PMC: 10514795. DOI: 10.3390/ncrna9050053. View

Zhuang G, Meng C, Guo X, Cheruku P, Shi L, Xu H . A novel regulator of macrophage activation: miR-223 in obesity-associated adipose tissue inflammation. Circulation. 2012; 125(23):2892-903. DOI: 10.1161/CIRCULATIONAHA.111.087817. View

Punthakee Z, Goldenberg R, Katz P . Definition, Classification and Diagnosis of Diabetes, Prediabetes and Metabolic Syndrome. Can J Diabetes. 2018; 42 Suppl 1:S10-S15. DOI: 10.1016/j.jcjd.2017.10.003. View

Huang C, Yang P, Huang Y, Chen S, Yang Y, Chen M . The role of circulating miRNAs in mechanism of action and prediction of therapeutic responses of metformin in polycystic ovarian syndrome. Fertil Steril. 2023; 119(5):858-868. DOI: 10.1016/j.fertnstert.2022.12.045. View

Karolina D, Armugam A, Tavintharan S, Wong M, Lim S, Sum C . MicroRNA 144 impairs insulin signaling by inhibiting the expression of insulin receptor substrate 1 in type 2 diabetes mellitus. PLoS One. 2011; 6(8):e22839. PMC: 3148231. DOI: 10.1371/journal.pone.0022839. View

10.

. ACOG Practice Bulletin No. 194: Polycystic Ovary Syndrome. Obstet Gynecol. 2018; 131(6):e157-e171. DOI: 10.1097/AOG.0000000000002656. View

11.

Huo Y, Ji S, Yang H, Wu W, Yu L, Ren Y . Differential expression of microRNA in the serum of patients with polycystic ovary syndrome with insulin resistance. Ann Transl Med. 2022; 10(14):762. PMC: 9372667. DOI: 10.21037/atm-22-2941. View

12.

Gonzalez-Arce L, Lara-Riegos J, Perez-Mendoza G, Rubi-Castellanos R, Vega-Marcin M, Valencia-Pacheco G . High expression levels of circulating microRNA-122 and microRNA-222 are associated with obesity in children with Mayan ethnicity. Am J Hum Biol. 2020; 33(6):e23540. DOI: 10.1002/ajhb.23540. View

13.

Zhao C, Liu X, Shi Z, Zhang J, Zhang J, Jia X . Role of serum miRNAs in the prediction of ovarian hyperstimulation syndrome in polycystic ovarian syndrome patients. Cell Physiol Biochem. 2015; 35(3):1086-94. DOI: 10.1159/000373934. View

14.

Hu M, Zheng S, Yin H, Zhu X, Lu F, Tong X . Identification of microRNAs that Regulate the MAPK Pathway in Human Cumulus Cells from PCOS Women with Insulin Resistance. Reprod Sci. 2020; 27(3):833-844. DOI: 10.1007/s43032-019-00086-5. View

15.

Hancerliogullari N, Tokmak A, Guney G, Kuru Pekcan M, Koc E, Candar T . Serum calprotectin levels as markers of inflammation, insulin resistance and hyperandrogenism in women with polycystic ovary syndrome. Medicine (Baltimore). 2023; 101(51):e32326. PMC: 9794328. DOI: 10.1097/MD.0000000000032326. View

16.

Mu J, Yu P, Li Q . microRNA-103 Contributes to Progression of Polycystic Ovary Syndrome Through Modulating the IRS1/PI3K/AKT Signal Axis. Arch Med Res. 2021; 52(5):494-504. DOI: 10.1016/j.arcmed.2021.01.008. View

17.

Yu L, Wang C, Zhang D, Liu M, Liu T, Pan B . Exosomal circ_0008285 in follicle fluid regulates the lipid metabolism through the miR-4644/ LDLR axis in polycystic ovary syndrome. J Ovarian Res. 2023; 16(1):113. PMC: 10268507. DOI: 10.1186/s13048-023-01199-x. View

18.

Yang Y, Ji C, Guo S, Su X, Zhao X, Zhang S . The miR-486-5p plays a causative role in prostate cancer through negative regulation of multiple tumor suppressor pathways. Oncotarget. 2017; 8(42):72835-72846. PMC: 5641172. DOI: 10.18632/oncotarget.20427. View

19.

Doycheva I, Ehrmann D . Nonalcoholic fatty liver disease and obstructive sleep apnea in women with polycystic ovary syndrome. Fertil Steril. 2022; 117(5):897-911. DOI: 10.1016/j.fertnstert.2022.03.020. View

20.

Cooney L, Dokras A . Beyond fertility: polycystic ovary syndrome and long-term health. Fertil Steril. 2018; 110(5):794-809. DOI: 10.1016/j.fertnstert.2018.08.021. View